Inhibition of Human Breast Cancer Cell Proliferation in Tissue Culture by the Neuroleptic Agents Pimozide and Thioridazine

Cancer Research

Volumn 50, Issue 17, 1990, Pages 5399-5405

  Strobl, Jeannine S ^a   Kirkwood, Keith L ^a   Lantz, Tracy K ^a   Lewine, Michael A ^a   Peterson, Virginia A ^a   Worley, Jennings F ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; N (4 AMINOBUTYL) 2 NAPSYLAMIDE; N (4 AMINOBUTYL) 5 CHLORO 2 NAPSYLAMIDE; PIMOZIDE; RADIOISOTOPE; THIORIDAZINE;

ARTICLE; BREAST CANCER; CYTOCHEMISTRY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DIVISION; CELL LINE; DNA REPLICATION; ESTRADIOL; FEMALE; HUMAN; KINETICS; PIMOZIDE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; THIORIDAZINE; THYMIDINE; TUMOR CELLS, CULTURED;

EID: 0025006630     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Seibert, K., and Lippman, M. Hormone receptors in breast cancer. Clin. Oncol., 7:735–794, 1982.
2. Karey, K. P., and Sirbasku, D. A. Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17β-estradiol. Cancer Res., 48:4083–4092, 1988.
3. Lippman, M. E., Dickson, R. B., Gelmann, E. P., Rosen, N., Knabbe, C., Bates, S., Bronzert, D., Huff, K., and Kasid, A. Growth regulation of human breast carcinoma occurs through regulated growth factor secretion. J. Cell. Biochem., 35:1–16, 1987.
4. Rozengurt, E., Erusalimsky, J., Mehmet, H., Morris, C., Nanberg, E., and Sinnett-Smith, J. Signal transduction in mitogenesis: further evidence for multiple pathways. Cold Spring Harbor Symp. Quant. Biol., 53: 945–954, 1988.
5. Hidaka, H., Susaki, Y., Tanaka, T., Endo, T., Ohno, S., Fujii, Y., and Nagata, T. N-(6-Aminohexyl)-5-chloronapthalenesulfonamide, a calmodulin antagonist, inhibits cell proliferation. Proc. Natl. Acad. Sci. USA, 78:4354–4357, 1981.
6. Wei, J. W., Hickie, R. A., and Klaassen, D. J. Inhibition of human breast cancer colony formation by anticalmodulin agents: trifluoperazine, W-7, and W-13. Cancer Chemother. Pharmacol., 11:86–90, 1983.
7. Kikuchi, Y., Iwano, I., and Kato, K. Effects of calmodulin antagonists on human ovarian cancer cell proliferation in vitro. Biochem. Biophys. Res. Commun., 123:385–392, 1984.
8. Hait, W. N., and Lee, G. L. Characteristics of the cytotoxic effects of the phenothiazine class of calmodulin antagonists. Biochem. Pharmacol., 34: 3973–3978, 1985.
9. Matsui, T., Nakao, Y., Kobayashi, N., Koizumi, T., Nakagawa, T., Kishihara, M., and Fujita, T. Effects of calmodulin antagonists and cytochalasins on proliferation and differentiation of human promyelocytic leukemia cell line HL-60. Cancer Res., 45:311–316, 1985.
10. Ford, J. M., Prozialeck, W. C., and Hait, W. N. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol. Pharmacol., 35:105–115, 1989.
11. Zinn, K., Keller, A., Whittemore, L. A., and Maniatis, T. 2-Aminopurine selectively inhibits the induction of β-interferon, c-fos, and c-myc gene expression. Science (Wash. DQ, 240:210–213, 1988.
12. Meyer, T., Regenass, V., Fabbro, D., Alteri, E., Rosel, J., Muller, M., Caravatti, G., and Matter, A. A derivative of staurosporine (CGP 41251) shows selectivity for protein kinase C inhibition and in vitro antiproliferative as well as in vivo anti-tumor activity. Int. J. Cancer, 43:851–856, 1989.
13. Matsumoto, H., and Sasaki, Y. Staurosporine, a protein kinase C inhibitor, interferes with proliferation of arterial smooth muscle cells. Biochem. Biophys. Res. Commun., 158:105–109, 1989.
14. Katayama, N., Nishikawa, M., Minami, N., and Shirakawa, S. Putative involvement of protein kinase C in proliferation of human myeloid progenitor cells. Blood, 73:123–130, 1989.
15. Jordan, V. C. (ed.). Estrogen/Antiestrogen Action and Breast Cancer Therapy. Madison, WI: University of Wisconsin Press, 1986.
16. Sutherland, R. L., Murphy, L. C., Foo, M. S., Green, M. D., Whybourne, A., and Krozowski, Z. S. High-affinity anti-oestrogen binding site distinct from the oestrogen receptor. Nature (Lond.), 288:273–275, 1980.
17. Kroeger, E. A., and Brandes, L. J. Evidence that tamoxifen is a histamine antagonist. Biochem. Biophys. Res. Commun., 131:750–755, 1985.
18. Hiemke, C., and Ghraf, R. Interactions of non-steroidal antiestrogens with dopamine-receptor binding. J. Steroid Biochem., 21:663–667, 1984.
19. Lam, H.-Y.P. Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem. Biophys. Res. Commun., 118: 27–32, 1984.
20. O'Brian, C. A., Liskamp, R. M., Solomon, D. H., and Weinstein, I. B. Inhibition of protein kinase C by tamoxifen. Cancer Res., 45: 2462–2465, 1985.
21. Greenberg, D. A., Carpenter, C. L., and Messing, R. O. Calcium channel antagonist properties of the antineoplastic antiestrogen tamoxifen in the PC 12 neurosecretory cell line. Cancer Res., 47:70–74, 1987.
22. Taylor, J. S., Blanchard, B., and Zava, D. T. Estrogen receptor-mediated and cytotoxic effects of antiestrogens tamoxifen and 4-hydroxytamoxifen. Cancer Res., 44:1409–1414, 1984.
23. Soule, H. D., Vazquez, J., Long, A., Albert, S., and Brennan, M. A human cell line from a pleural effusion derived from a breast carcinoma. J. Natl. Cancer Inst., 51:1409–1413, 1973.
24. Engel, L. W., Young, N. A., Tralka, T. S., Lippman, M. E., O'Brien, S. J., and Joyce, M. J. Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Res., 38: 3352–3364, 1978.
25. Keydar, I., Chen, L., Karby, S., Weiss, F. R., Delarea, J., Radu, M., Chaitcik, S., and Brenner, H. J. Establishment and characterization of a cell line of human breast carcinoma origin. Eur. J. Cancer, 15:659–670, 1979.
26. Cailleau, R., Young, R., Olive, M., and Reeves, W. J., Jr. Breast tumor cell lines from pleural effusions. J. Natl. Cancer Inst., 53:661–666, 1974.
27. Strobl, J. S., and Lippman, M. E. Prolonged retention of estradiol by human breast cancer cells in tissue culture. Cancer Res., 39:3319–3327, 1979.
28. Vindelov, L. L. Flow microfluorometric analysis of nuclear DNA in cells from solid tumors and cell suspensions. Virchows Arch. B ZellPathol., 24: 227–242, 1977.
29. Strobl, J. S., Kasid, A., Huff, K. K., and Lippman, M. E. Kinetic alterations in estrogen receptors associated with estrogen receptor processing in human breast cancer cells. Endocrinology, 115:1116–1124, 1984.
30. Scatchard, G. The attraction of proteins for small molecules. Ann. NY Acad. Sci., 57:660–672, 1949.
31. Clark, J. H., Peck, E. J., Markaverich, B. M., and Densmore, C. L. Basic Principles and Measurement of Steroid Hormone Receptors. Itu M. R. Hughes, W. T. Schrader, and B. W. O'Malley (eds.), Hormone Action and Molecular Endocrinology, pp. 1–47. Houston: Biological Associates, Inc., 1990.
32. Nardulli, A. M., Greene, G. L., O'Malley, B. W., and Katzenellenbogen, B. S. Regulation of progesterone receptor messenger RNA and protein levels in MCF-7 cells by estradiol: analysis of estrogen's effect on progesterone receptor synthesis and degradation. Endocrinology, 122: 935–944, 1988.
33. Bontenbal, M., Sieuwerts, A. M., Klijn, J. G. M., Peters, H. A., Krijnen, H. L. J. M., Sonneveld, P., and Foekens, J. A. Effect of hormonal manipulation and doxorubicin administration on cell cycle kinetics of human breast cancer cells. Br. J. Cancer, 60:688–692, 1989.
34. Levin, R. M., and Weiss, B. Mechanism by which psychotropic drugs inhibit adenosine cyclic 3’,5’-monophosphate phosphodiesterase of brain. Mol. Pharmacol., 12:581–589, 1976.
35. Sutherland, R. L., Watts, C. K. W., Hall, R. E., and Ruenitz, P. C. Mechanisms of growth inhibition by nonsteroidal antioestrogens in human breast cancer cells. J. Steroid Biochem., 27:891–897, 1987.
36. Musgrove, E. A., Wakeling, A. E., and Sutherland, R. L. Points of action of estrogen antagonists and a calmodulin antagonist within the MCF-7 human breast cancer cell cycle. Cancer Res., 49:2398–2404, 1989.
37. Taylor, I. W., Hodson, P. J., Green, M. D., and Sutherland, R. L. Effects of tamoxifen on cell cycle progression of synchronous MCF-7 human mammary carcinoma cells. Cancer Res., 43:4007–4010, 1983.
38. Rasmussen, C. D., and Means, A. R. Calmodulin is involved in regulation of cell proliferation. EMBO J., 6:3961–3968, 1987.
39. Miglaccio, A., Rotondi, A., and Auricchio, F. Calmodulin-stimulated phosphorylation and 17 β-estradiol receptor on tyrosine. Proc. Natl. Acad. SCi. USA, 81:5921–5925, 1984.
40. Auricchio, F., Migliaccio, A., DiDomenico, M., and Nola, E. Oestradiol stimulates tyrosine phosphorylation and hormone binding activity of its own receptor in a cell-free system. EMBO J., 6:2923–2929, 1987.
41. Lam, H. Y., and Chan, A. C. Calmodulin antagonists inhibit specific uptake of estradiol by human breast cancer cells. Proc. Am. Assoc. Cancer Res., 29: A987, 1988.
42. Guilino, A., Barrera, G., Vacca, A., Farina, A., Ferretti, C., Screpanti, I., Dianzani, M. U., and Frati, L. Calmodulin antagonism and growth-inhibiting activity of triphenylethylene antiestrogens in MCF-7 human breast cancer cells. Cancer Res., 46:6274–6278, 1986.
43. Gould, R. J., Murphy, K. M. M., Reynolds, I. J., and Snyder, S. H. Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists. Proc. Natl. Acad. Sci. USA, 80:5122–5125, 1983.
44. Flaim, S. F., Brannan, M. D., Swigart, S. C., Gleason, M. M., and Muschek, L. D. Neuroleptic drugs attenuate calcium influx and tension development in rabbit thoracic aorta: effects of pimozide, penfluridol, chlorpromazine, and haloperidol. Proc. Natl. Acad. Sci. USA, 82:1237–1241, 1985.
45. Galizzi, J.-P., Fosset, M., Romey, G., Laduron, P., and Lazdunski, M. Neuroleptics of the diphenylbutylpiperidine series are potent calcium channel inhibitors. Proc. Natl. Acad. Sci. USA, 83: 7513–7517, 1986.
46. + antagonists. Am. J. Physiol., 253: C162–C170, 1987.
47. Worley, J. F., III, and Strobl, J. S. Voltage-dependent calcium channels in MCF-7 human breast cancer cells and inhibition of cell growth by calcium channel antagonists. Cancer Chemother. Pharmacol., 24(Suppl. 2): S84, 1989.
48. Aftab, D. T., and Hait, W. N. A semiautomated 96-well plate assay for protein kinase C. Anal. Biochem., 187:84–88, 1990.
49. Guilband, N., Pichon, M. F., Faye, J. C., Bayard, F., and Valette, A. Modulation of estrogen receptors by phorbol diesters in human breast MCF-7 cell line. Mol. Cell. Endocrinol., 56:157–163, 1988.
50. Dubik, D., and Shiu, R. P. C. Transcriptional regulation of c-myc oncogene expression by estrogen in hormone-responsive human breast cancer cells. J. Biol. Chem., 263:12705–12708, 1988.
51. Sommercorn, J., Mulligan, J. A., Lozeman, F. J., and Krebs, E. G. Activation of casein kinase II in response to insulin and to epidermal growth factor. Proc. Nad. Acad. Sci. USA, 84:8834–8838, 1987.
52. Klarlund, J. K., and Czech, M. P. Insulin-like growth factor I and insulin rapidly increase casein kinase II activity in BALB/c3T3 fibroblasts. J. Biol. Chem., 263:15872–15875, 1988.
53. Luscher, B., Kuenzel, E. A., Krebs, E. G., and Eisenman, R. W. Myc oncoproteins are phosphorylated by casein kinase II. EMBO J., 8: 1111–1119, 1989.
54. Baldessarini, R. J. Drugs and the treatment of psychiatric disorders. In: A. G. Gilman, L. S. Goodman, T. W. Rail, and F. Murad (eds.), The Pharmacological Basis of Therapeutics, pp. 387–445. New York: MacMillan Publishing Co., 1985.
55. Murphy, K. M. M., Gould, R. J., Largent, B. L., and Snyder, S. H. A unitary mechanism of calcium antagonist drug action. Proc. Natl. Acad. Sci. USA, 80:860–864, 1983.
56. Musey, V. C., Collins, D. C., Musey, P. I., Martino-Saltzman, D., and Preddy, J. R. K. Long-term effect of a first pregnancy on the secretion of prolactin. N. Engl. J. Med., 316:229–234, 1987.
57. Kleinberg, D. L. Prolactin and breast cancer. N. Engl. J. Med., 316: 269–271, 1987.
58. Ben-David, M., Kadar, T., Wittliff, J., Biran, S., and Schally, A. Characterization of prolactin receptors and their distribution among American and Israeli women with breast cancer: implications for prediction of hormonal dependency and treatment. Biomed. Pharmacother., 42:101–109, 1988.
59. Dauvois, S., Spinola, P. G., and Labrie, F. Additive inhibitory effects of bromocryptine (CB-154) and medroxyprogesterone acetate (MPA) on di-methylbenz[a]anthracene (DMBA)-induced mammary tumors in the rat. Eur. J. Cancer Clin. Oncol., 25:891–897, 1989.